PT-141 (Bremelanotide) and Bone Health: What Women Need to Know

What Is Bremelanotide and Why Does Bone Health Come Up?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in June 2019 under the brand name Vyleesi specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). It works centrally, activating melanocortin receptors in the brain rather than acting on vascular or hormonal pathways the way older sexual-health drugs do.

Bone health enters the conversation because melanocortin receptors, the same family PT-141 targets, are expressed in skeletal tissue. MC1R, MC2R, and MC5R have all been identified on osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells). That receptor overlap is biologically plausible. Whether it translates into a clinical signal at the dose and frequency a woman actually uses the drug is a different question, and one the evidence answers more modestly than some online forums suggest.

The Melanocortin System at a Glance

The melanocortin system includes five G-protein-coupled receptors, MC1R through MC5R. Bremelanotide has affinity for MC1R, MC3R, MC4R, and MC5R, with its desired central effect on sexual desire mediated primarily through MC4R in the hypothalamus. The adrenocorticotropic hormone (ACTH) analog connection is relevant here: MC2R, the primary ACTH receptor, sits on adrenal cells but also on bone-forming osteoblasts, which is why researchers initially flagged cortisol-related bone implications for drugs in this class.

Why Women Ask About This Specifically

Women carry a disproportionate share of osteoporosis risk. Approximately 80% of the 10 million Americans with osteoporosis are women, and bone loss accelerates sharply in the first two to five years after the final menstrual period. A premenopausal woman prescribed bremelanotide may be in her late 30s or 40s, already approaching perimenopause, and reasonably wants to know whether this drug adds to that trajectory. That is a legitimate clinical question, not an overreaction.

What the RECONNECT Trials Actually Measured (and Did Not Measure)

The RECONNECT program, published in Obstetrics and Gynecology in 2019, comprised two phase 3, randomized, double-blind, placebo-controlled trials (studies 301 and 302) enrolling premenopausal women with generalized, acquired HSDD. The primary endpoints were the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm item 13 score measured over 24 weeks.

What RECONNECT Found

Both trials showed statistically significant improvement in HSDD symptoms. In pooled analysis, women using bremelanotide reported a mean increase of 0.5 points on the desire domain (vs 0.2 for placebo) and a clinically meaningful reduction in distress scores. Nausea occurred in approximately 40% of bremelanotide users versus 1% placebo, making it the most common discontinuation reason.

What RECONNECT Did Not Measure

Bone mineral density (BMD) was not a prespecified endpoint in RECONNECT. The trials ran 24 weeks, a time frame too short to detect meaningful DXA changes under most circumstances. No DEXA scans, no bone turnover markers (CTX, P1NP), and no fracture data appear in the published results. This is a real evidence gap, and you deserve to know it plainly rather than have it papered over with vague reassurance.

Melanocortin Receptors and Bone Biology: The Science Behind the Question

Understanding whether bremelanotide could theoretically affect bone requires a brief look at what melanocortin signaling does in skeletal tissue. This framework does not appear in most patient-facing summaries of PT-141, but it is the correct lens for evaluating the question.

MC1R and Osteoclast Activity

MC1R is expressed on osteoclast precursors. In animal models, alpha-melanocyte-stimulating hormone (alpha-MSH), an endogenous melanocortin, suppresses osteoclast differentiation and activity, which would theoretically be bone-protective. Bremelanotide shares structural similarities with alpha-MSH. If this receptor-level effect translates to humans, the drug might mildly reduce bone resorption rather than accelerate it, but this has not been studied in clinical populations.

MC2R, ACTH, and Cortisol-Bone Coupling

MC2R mediates ACTH action on the adrenal cortex, which controls cortisol production. Chronic cortisol elevation is one of the best-established drivers of secondary osteoporosis in women, the mechanism behind glucocorticoid-induced bone loss. Bremelanotide does have some MC2R affinity, raising the theoretical question of adrenal stimulation. At the approved 1.75 mg as-needed dose, used roughly once per week by most participants in RECONNECT, sustained cortisol elevation has not been demonstrated. Intermittent, infrequent receptor activation is pharmacologically distinct from the continuous ACTH stimulation seen in pituitary adenomas.

MC4R and Energy-Bone Cross-Talk

MC4R, the primary target for bremelanotide's desired effect, is also expressed in the hypothalamus where it integrates energy balance signals. Leptin, a hormone produced by fat cells, regulates bone density partly through MC4R signaling pathways. Women with very low body weight or hypothalamic amenorrhea have suppressed leptin and lower BMD. This is mechanistically distinct from bremelanotide use, but it illustrates that the hypothalamic melanocortin axis and skeletal health are genuinely connected systems. The drug does not mimic the nutritional deprivation state and does not suppress leptin.

How Your Hormonal Status Changes the Calculus

Bone health in women is inseparable from estrogen status. Estrogen suppresses RANKL-driven osteoclast activity. When estrogen falls, bone resorption accelerates. The drug you are taking for HSDD does not change your estrogen level, but your estrogen level changes the context in which you are taking it.

Reproductive Years (Approximately Ages 18 to 40)

In a woman with regular cycles and normal estrogen, bone is at or near peak mass. HSDD in this life stage is often acquired after a pregnancy, postpartum hormonal changes, or chronic stress. Bremelanotide is approved precisely for this population. At this stage, baseline bone risk is low, and the theoretical melanocortin-receptor effects on bone, whatever they ultimately prove to be, are operating against a background of adequate estrogen protection.

Perimenopause (Approximately Ages 40 to 52)

This is where clinical nuance matters most. A perimenopausal woman may have irregular cycles, fluctuating and declining estrogen, and accelerating bone turnover that predates her last period by several years. Bremelanotide is not FDA-approved for postmenopausal women, but a woman at 47 with irregular cycles technically remains premenopausal by definition while already experiencing significant bone changes. If your clinician is considering this drug in your late 40s, ask whether a baseline DXA scan makes sense given your overall risk profile, independently of the drug.

Postmenopause

Bremelanotide has not been studied for efficacy or safety in postmenopausal women, and its approval explicitly covers premenopausal women only. Off-label use in postmenopause is therefore doubly uncertain: the efficacy data do not apply, and any bone effects would play out against a background of already-reduced estrogen and actively declining BMD.

PCOS

Women with PCOS have a complex metabolic phenotype that includes higher androgen levels, insulin resistance, and often anovulation. Some PCOS research suggests higher bone density in hyperandrogenic phenotypes, which may be partly protective. HSDD is reported at higher rates in women with PCOS, making this drug potentially relevant to this population. No dedicated PCOS-specific bremelanotide bone data exist.

Pregnancy, Lactation, and Contraception: A Required Conversation

Bremelanotide is contraindicated during pregnancy. This is not a soft recommendation. The FDA prescribing information states that bremelanotide may impair luteal phase support through melanocortin-mediated effects and carries the risk of fetal harm based on animal reproductive data, where fetal malformations were observed at doses producing plasma exposures comparable to the clinical dose.

What to Do Before Trying to Conceive

Discontinue bremelanotide before attempting pregnancy. Because it is used on an as-needed basis rather than as a daily medication, this means simply stopping use and not resuming until any pregnancy is confirmed to have concluded. There is no defined washout period specified in the label, but given its short half-life (approximately 2.7 hours), the drug itself clears quickly. The concern is not accumulation but rather use during an undetected early pregnancy.

Contraception Requirement

The FDA label recommends that women use contraception during bremelanotide treatment. This is particularly relevant because HSDD is sometimes addressed in a relational context where pregnancy is not planned but is not actively prevented either. Have this conversation explicitly with your prescriber.

Bremelanotide and Hormonal Contraceptives: An Interaction Worth Knowing

Bremelanotide slows gastric motility when injected. This transiently reduces oral drug absorption for roughly one hour after use. If you take a combined oral contraceptive pill, taking it at least one hour before or after the bremelanotide injection minimizes any potential absorption effect. This is not a large interaction, but it is specific and actionable.

Lactation

Human data on bremelanotide transfer into breast milk do not exist. Animal studies have not been completed to characterize this. The standard guidance applies: the potential for adverse effects on a nursing infant cannot be excluded. Avoid use during breastfeeding, or pump and discard for a conservative interval given the short half-life if a single use occurs.

Who This Drug Is Right for, and Who Should Think Carefully

A Good Candidate

A premenopausal woman with acquired, generalized HSDD who has been with her partner for at least six months, who is distressed by her reduced desire (not simply less interested due to relationship factors), who does not have cardiovascular disease or uncontrolled hypertension, and who is using reliable contraception. She should understand that the drug is not hormonal, will not change her cycle, and is taken only when she anticipates sexual activity within approximately 45 minutes to 1 hour.

Women Who Need Extra Caution or Are Not Good Candidates

Women with known cardiovascular disease or those on antihypertensive medications require extra caution because bremelanotide produces a transient decrease in blood pressure (mean decrease of approximately 6 mmHg systolic and 3 mmHg diastolic in trials), which can compound existing hemodynamic vulnerabilities. Women who are pregnant or breastfeeding should not use this drug. Women with a high Framingham cardiovascular risk score and those on medications that prolong the QT interval warrant a careful prescriber review.

Women with a history of hyperpigmentation disorders should note that bremelanotide activates MC1R, the primary melanocortin receptor governing skin pigmentation. Focal hyperpigmentation of the face, breast, and gums was reported in approximately 1% of users in clinical trials and may persist after discontinuation.

Practical Monitoring Recommendations for Bone Health

Given the absence of dedicated bone-density data, here is a practical framework for women and their prescribers, organized by baseline risk.

Low Baseline Bone Risk (Premenopausal, Regular Cycles, No Glucocorticoid Use)

No bone-specific monitoring is required beyond what your general preventive care already includes. Ensure adequate calcium intake (1,000 mg per day through diet where possible) and vitamin D sufficiency (serum 25-OH-D above 30 ng/mL, targeting 40 to 60 ng/mL in many women). A FRAX score calculation at your next annual visit is reasonable for women over 40.

Moderate to High Baseline Bone Risk (Perimenopause, Prior Fragility Fracture, Eating Disorder History, Prolonged Glucocorticoid Use)

Consider a baseline DXA scan before or shortly after starting bremelanotide, not necessarily because of the drug itself but because your clinical picture warrants it. This gives your clinician a reference point. If you are in perimenopause and your DXA shows osteopenia (T-score between -1.0 and -2.5), discuss whether concomitant bone protection strategies, including calcium, vitamin D, weight-bearing exercise, or hormone therapy, belong in your plan.

What to Ask Your Prescriber

Ask specifically whether your HSDD has a hormonal contributor. Low androgen levels, thyroid dysfunction, or low estrogen can all reduce sexual desire and also affect bone. A targeted labs panel (total and free testosterone, DHEAS, TSH, estradiol) may identify a treatable driver of both your HSDD and any emerging bone risk, making bremelanotide part of a broader rather than standalone plan.

Current Evidence Gaps and What Research Is Needed

Women have been historically underrepresented in pharmacokinetic and safety trials, and bone health has rarely been a primary endpoint in sexual-health drug trials. To be direct: the connection between bremelanotide and bone density at clinical doses remains essentially unstudied. What exists is mechanistic plausibility (melanocortin receptors on bone cells), animal data that points more toward bone protection than harm at the alpha-MSH level, and a 24-week human trial that was not designed to answer this question.

What would actually settle the matter is a 12-month trial with serial DXA and bone turnover markers (P1NP for formation, CTX for resorption) in premenopausal and perimenopausal women using bremelanotide at the approved frequency. No such trial has been registered or published as of this writing. The FDA post-marketing commitment for bremelanotide does not include a bone-density study.

This gap is not unique to bremelanotide. Flibanserin, the other FDA-approved HSDD medication, similarly lacks dedicated long-term bone data in premenopausal women. The field as a whole has not prioritized skeletal endpoints in female sexual health drug development.

A Note on Off-Label PT-141 Use in Wellness Contexts

Compounded PT-141 is sold through some telehealth and online pharmacies without an HSDD diagnosis, sometimes in doses higher than the FDA-approved 1.75 mg, and occasionally marketed for both men and women. In this context, the bone-health question becomes harder to answer because compounded versions have not undergone the same safety profiling. Higher doses may have more pronounced effects at all melanocortin receptor subtypes, including those in bone and adrenal tissue. The absence of a clinical signal at 1.75 mg does not mean the absence of a signal at 2.5 mg or 5 mg, doses circulating in some compounding formulations.

If you are using compounded PT-141 rather than FDA-approved Vyleesi, your prescriber should be aware of the dose discrepancy and its implications for all safety parameters, bone included.

Bremelanotide: The 2025 Clinical Update

Since the RECONNECT publication, no major new randomized data have emerged specifically on bremelanotide efficacy or safety in female populations. The FDA label update from the original 2019 approval remains the current prescribing reference. Real-world prescribing has been modest: flibanserin holds a larger share of the HSDD market, partly because it is a daily oral medication rather than an injectable as-needed one, which many women prefer for discretion and convenience.

Research into melanocortin receptor agonists for female sexual dysfunction continues, with MC4R-selective agonists under investigation in preclinical settings. These agents might carry a different receptor-subtype bone profile than bremelanotide, depending on how selective they prove to be. That work remains years from clinical trials.

The Menopause Society (formerly NAMS) continues to emphasize that bone loss prevention in women is best addressed through a combination of adequate estrogen status, mechanical loading, calcium, and vitamin D, with pharmacological agents reserved for women who meet DXA and FRAX thresholds. Bremelanotide does not substitute for any of those interventions and should not be expected to.